Multiple SclerosisPhase 3NCT00649792
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial
A Phase 3 study testing Fampridine-SR in people with Multiple Sclerosis, run by Acorda Therapeutics at 42 sites in 2 countries.
Trial summary
The purpose of the study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months in patients who previously participated in the MS-F204 study or until it becomes commercially available, whichever comes first. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Multiple Sclerosis
- What is being tested?
- Fampridine-SR
- Type of treatment
- Pill or oral medicine
- How many people
- 214 participants
- Where
- 42 sitesin 2 countries
- Study dates
- Aug 2007to Apr 2011
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient must have been previously enrolled in the Acorda Therapeutics MS-F204 study and received either Fampridine-SR or placebo
- Patient with clinically defined multiple sclerosis (the diagnostic criteria based on: McDonald WI, et al. Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Annals of Neurology. 2001; 50: 121-127)
- Patient must be at least 18 years of age. Any patient who is now over the age of 70 must be in good overall health in the judgment of the investigator
- Patient must be of adequate cognitive function, as judged by the Investigator
- Patients who are women of childbearing potential must have a negative urine pregnancy test at the screening visit
Who cannot join
- Female patients who are either pregnant or breastfeeding.
- Women of childbearing potential who are not using a specified birth control method
- Patients discontinued prematurely from the MS-F204 study
- Patients with a history of seizures or with evidence of past, or possible epileptiform activity on an EEG
- Patient with either a clinically significant abnormal ECG or laboratory values at the MS-F204 EXT screening visit
- Patient with severe renal impairment
Show all 10Show fewer
- Patient with angina, uncontrolled hypertension, clinically significant cardiac arrhythmias, or any other clinically significant cardiovascular abnormality, as judged by the Investigator
- Patient with a known allergy to pyridine-containing substances or any of the inactive ingredients of the Fampridine-SR tablet
- Patient who has received an investigational drug (other than Fampridine-SR or placebo under MS-F204 study) within 30 days of the MS-F204EXT screening visit or a patient who is scheduled to enroll in an investigational drug trial at any time during this study
- Patient who has a history of drug or alcohol abuse within the past year
Trial locations and contacts
42 sites in 2 countries.
42 sites in 2 countries
United States38 sites
Shepherd Center
Atlanta, Georgia, 30309
Maryland Center for MS
Baltimore, Maryland, 21201
Neurological Research Center, Inc.
Bennington, Vermont, 05201
Alta Bates Summit Medical Center - Research and Education Institute
Berkeley, California, 94705
The Center for Neurological Services
Bismarck, North Dakota, 58501
Jacobs Neurological Institute Buffalo General Hospital
Buffalo, New York, 14203
Fletcher Allen Health Care
Burlington, Vermont, 05401
CAMC Health Education & Research Institute
Charleston, West Virginia, 25304
CMC - Neuroscience & Spine Institute, Division of Neurology
Charlotte, North Carolina, 28207
University of Chicago
Chicago, Illinois, 60637
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
Ohio State University MS Center
Columbus, Ohio, 43221
Wayne State University, Department of Neurology
Detroit, Michigan, 48201
Neurological Associates
Fayetteville, Arkansas, 72703
The Schapiro Center for MS
Golden Valley, Minnesota, 55422
Advanced Neurology Specialists
Great Falls, Montana, 59405
Indiana University MS Center
Indianapolis, Indiana, 46202
MS Center at Evergreen
Kirkland, Washington, 98034
Associates in Neurology, PSC
Lexington, Kentucky, 40503
Lahey Clinic
Lexington, Massachusetts, 02421
USC, Keck School of Medicine Health Care Consultation Center
Los Angeles, California, 90033
Center for Neurological Disorders of Aurora, St. Luke's Medical Center
Milwaukee, Wisconsin, 53215
Yale University MS Center
New Haven, Connecticut, 06510
Corinne Goldsmith Dickinson Center for MS
New York, New York, 10029
Columbia University Multiple Sclerosis Clinical Care Center
New York, New York, 10032
UMDNJ
Newark, New Jersey, 07103
Consultants in Neurology, Ltd.
Northbrook, Illinois, 60062
Thomas Jefferson University Physicians
Philadelphia, Pennsylvania, 19107
Barrow Neurology Clinic, St. Joseph's Hospital and Medical Center
Phoenix, Arizona, 85013
HOPE Research Institute
Phoenix, Arizona, 85050
Oregon Health & Science University, MS Center of Oregon, UHS-42
Portland, Oregon, 97239
Raleigh Neurology Associates
Raleigh, North Carolina, 27607
University of Rochester
Rochester, New York, 14642
UC Davis
Sacramento, California, 95817
Washington University School of Medicine
St Louis, Missouri, 63110
SUNY Stony Brook
Stony Brook, New York, 11794
Gimbel MS Center at Holy Name Hospital
Teaneck, New Jersey, 07666
Wake Forest University, Dept of Neurology, M.S. Research
Winston-Salem, North Carolina, 27157
Canada4 sites
Foothills Medical Center
Calgary, Alberta, T2N 2T9
River Valley Health c/o Stan Cassidy Centre for Rehabilitation
Fredericton, New Brunswick, E3B 0C7
QEII Health Sciences Centre, Nova Scotia Rehabilitation Centre Site
Halifax, Nova Scotia, B3H 4K4
University of British Columbia, Vancouver Coastal Health Research Institute
Vancouver, British Columbia, V6T 2B5
About this study
Official title: Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial
The purpose of the study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months in patients who previously participated in the MS-F204 study or until it becomes commercially available, whichever comes first.
Read the detailed description
Multiple sclerosis (MS) is a disorder of the body's immune system that affects the central nervous system (CNS). Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain and the arms and legs. In people with MS, the fatty sheath that surrounds and insulates the nerve fibers (called "myelin") deteriorates, causing nerve impulses to be slowed or stopped. As a result, patients with MS may experience periods of muscle weakness and other symptoms such as numbness, loss of vision, loss of coordination, paralysis, spasticity, mental and physical fatigue and a decrease in the ability to think and/or remember. These periods of illness may come (exacerbations) and go (remissions). Fampridine-SR is an experimental drug that has been reported to possibly improve muscle strength and walking ability for some people with MS. This study will evaluate the effects and possible risks of taking Fampridine-SR in MS patients over a long period of time.
- Conditions
- Multiple Sclerosis
- Being tested
- Fampridine-SR
- Keywords
- multiple sclerosis, MS, walking, leg strength, demyelination
- Medical subject headings
- Multiple Sclerosis, Demyelinating Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fampridine-SRDrug
Also called 4-aminopyridine
Tablets, 10 mg, BID (twice daily)
What is being measured
The primary outcome is the main question the study is designed to answer.
Summary of Treatment Emergent Adverse Events (TEAE).
All adverse events reported were treatment emergent. Therefore, events that had a date of onset, or worsening, on or after the start of the open-label drug and up to 14 days after the last dose (for non-serious events) or up to 30 days after the last dose (for SAEs) were summarized. Any abnormal clinically significant changes in physical examination, medical history, clinical laboratory testing, 12-lead ECG, and standard EEG testing were captured as adverse events.
Measured: up to 40 months
Secondary outcomes (4)
Timed 25-Foot Walk (T25FW)
Measured: Week 2, 14, 26, continuing every 26 weeks until the Final Visit
Subject Global Impression (SGI)
For the SGI, the potential responses to the effects of the investigational drug during the preceding week were 1=terrible, 2=unhappy, 3=mostly dissatisfied, 4=neutral/ mixed, 5=mostly satisfied, 6=pleased, and 7=delighted.
Measured: Visit 1 and every clinic visit thereafter (other than the follow-up visit)
Clinician's Global Impression (CGI)
The potential responses were 1=very much improved, 2=much improved, 3=somewhat improved, 4=no change, 5=somewhat worse, 6=much worse, and 7=very much worse.
Measured: Visit 1 and every clinic visit thereafter
Expanded Disability Status Scale (EDSS)
The EDSS was used to grade patient disability on a scale from 0.0 (normal neurological exam) to 10.0 (death)
Measured: The Screening Visit, Visit 6, Final Visit or Early Termination Visit (if applicable)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Apr 2008 (estimated)
- Study startAug 2007
- Primary completionJan 2011
- Study completionApr 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 214 participants (actual)
Sponsor and investigators
- Lead sponsor
- Acorda Therapeutics
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Bonnie Faust, Study director, Acorda Therapeutics
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00649792
- Sponsor's protocol ID
- MS-F204 EXT
- Status last verified
- Jan 2012
- First submitted
- 28 Mar 2008
- Last updated
- 28 Feb 2012
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 28 Feb 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial
- ClinicalTrials.gov ID
- NCT00649792
- Acronym / sponsor ID
- MS-F204 EXT
- Conditions
- Multiple Sclerosis
- Keywords
- multiple sclerosis, MS, walking, leg strength, demyelination
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 214 participants (actual)
- Lead sponsor
- Acorda TherapeuticsIndustry (pharma, biotech, devices)
- Study start
- Aug 2007
- Primary completion
- Jan 2011 (actual)
- Study completion
- Apr 2011 (actual)
- First posted
- 1 Apr 2008 (estimated)
- Results
- Posted 27 Feb 2012
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months in patients who previously participated in the MS-F204 study or until it becomes commercially available, whichever comes first.
Detailed description
Multiple sclerosis (MS) is a disorder of the body's immune system that affects the central nervous system (CNS). Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain and the arms and legs. In people with MS, the fatty sheath that surrounds and insulates the nerve fibers (called "myelin") deteriorates, causing nerve impulses to be slowed or stopped. As a result, patients with MS may experience periods of muscle weakness and other symptoms such as numbness, loss of vision, loss of coordination, paralysis, spasticity, mental and physical fatigue and a decrease in the ability to think and/or remember. These periods of illness may come (exacerbations) and go (remissions). Fampridine-SR is an experimental drug that has been reported to possibly improve muscle strength and walking ability for some people with MS. This study will evaluate the effects and possible risks of taking Fampridine-SR in MS patients over a long period of time.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Patient must have been previously enrolled in the Acorda Therapeutics MS-F204 study and received either Fampridine-SR or placebo
- Patient with clinically defined multiple sclerosis (the diagnostic criteria based on: McDonald WI, et al. Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Annals of Neurology. 2001; 50: 121-127)
- Patient must be at least 18 years of age. Any patient who is now over the age of 70 must be in good overall health in the judgment of the investigator
- Patient must be of adequate cognitive function, as judged by the Investigator
- Patients who are women of childbearing potential must have a negative urine pregnancy test at the screening visit
Key exclusion criteria (10 listed)
- Female patients who are either pregnant or breastfeeding.
- Women of childbearing potential who are not using a specified birth control method
- Patients discontinued prematurely from the MS-F204 study
- Patients with a history of seizures or with evidence of past, or possible epileptiform activity on an EEG
- Patient with either a clinically significant abnormal ECG or laboratory values at the MS-F204 EXT screening visit
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fampridine-SRAlso: 4-aminopyridineTablets, 10 mg, BID (twice daily) | Drug | – |
Primary outcome
Summary of Treatment Emergent Adverse Events (TEAE).
Time frame: up to 40 months
All adverse events reported were treatment emergent. Therefore, events that had a date of onset, or worsening, on or after the start of the open-label drug and up to 14 days after the last dose (for non-serious events) or up to 30 days after the last dose (for SAEs) were summarized. Any abnormal clinically significant changes in physical examination, medical history, clinical laboratory testing, 12-lead ECG, and standard EEG testing were captured as adverse events.
4 secondary outcomes
Timed 25-Foot Walk (T25FW)
Time frame: Week 2, 14, 26, continuing every 26 weeks until the Final Visit
Subject Global Impression (SGI)
Time frame: Visit 1 and every clinic visit thereafter (other than the follow-up visit)
Clinician's Global Impression (CGI)
Time frame: Visit 1 and every clinic visit thereafter
Expanded Disability Status Scale (EDSS)
Time frame: The Screening Visit, Visit 6, Final Visit or Early Termination Visit (if applicable)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Feb 2012.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Click here for more information about Fampridine-SR clinical trialsLink provided by the sponsor.
Related trials for Multiple Sclerosis
RecruitingPhase 3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Relapsing Multiple Sclerosis
Active, not recruitingObservational study
A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)
Multiple Sclerosis
RecruitingObservational study
Study of Skin Tumors in Tuberous Sclerosis
Tuberous Sclerosis
Recruiting
The Effects of Synchronous and Asynchronous Pilates Training Based on Telerehabilitation on Core Stabilization, Balance, Cognitive Functions, and Quality of Life in Individuals With Multiple Sclerosis: A Single-Blind Randomized Controlled Trial
Multiple Sclerosis
RecruitingObservational study
Care in Multiple Sclerosis (MS)
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bonnie Faust study director
Acorda Therapeutics
42 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Fampridine-SR in people with Multiple Sclerosis, run by Acorda Therapeutics at 42 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Feb 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 42 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 27 Feb 2012). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Summary of Treatment Emergent Adverse Events (TEAE). (time frame: up to 40 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Feb 2012.